Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.730
-0.011 (-1.46%)
At close: Dec 5, 2025, 4:00 PM EST
0.730
-0.000 (-0.03%)
After-hours: Dec 5, 2025, 7:38 PM EST
Xilio Therapeutics Revenue
Xilio Therapeutics had revenue of $19.07M in the quarter ending September 30, 2025, with 742.51% growth. This brings the company's revenue in the last twelve months to $31.80M, up 588.40% year-over-year. In the year 2024, Xilio Therapeutics had annual revenue of $6.34M.
Revenue (ttm)
$31.80M
Revenue Growth
+588.40%
P/S Ratio
1.19
Revenue / Employee
$496,938
Employees
64
Market Cap
38.34M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XLO News
- 22 days ago - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 25 days ago - Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript - Seeking Alpha
- 4 weeks ago - Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - GlobeNewsWire